The market for Glucagon-like peptide-1 analogues is predicted to develop because to the high prevalence of diabetes in the US and Asia-Pacific.

Glucagon-like peptide-1 (GLP-1) analogues, also known as incretin mimetics, are a type of diabetic medication used to lower blood sugar levels in people with type 2 diabetes. GLP-1 analogues block GLP-1 breakdown, increasing glucose-dependent insulin release, suppressing glucagon release (lowering hepatic glucose output), and slowing gastric emptying (resulting in weight loss from reduced appetite). GLP-1 analogues, unlike other anti-diabetic medicines, do not produce hypoglycemia. In addition, GLP-1 analogues help people lose weight.


High prevalence of diabetes in the U.S. and Asia-Pacific is expected to drive the growth of Glucagon-like peptide-1 analogs market

According to the International Diabetes Federation's (IDF) Diabetes Atlas 2017, diabetes affects over 425 million people globally. According to a 2017 World Health Organization (WHO) report, diabetes is one of the top three noncommunicable illness causes of death. The top three economies with a high incidence of diabetes are China (114.4 million), India (72.9 million), and the United States (30.2 million). The Glucagon-like peptide-1 analogs market would have a huge growth opportunity with such a high incidence rate. This is due to the fact that there are roughly 212.4 million people living with undiagnosed diabetes worldwide. According to the International Diabetes Federation (IDF), the United States has the greatest prevalence of diabetes (13 percent of the population), which is projected to promote the growth of the glucagon-like peptide-1 analogues market due to their low cost and high market penetration. According to a study published in the Journal of American Health and Drug Benefit, GLP-1 analogues act not only in type 2 diabetes but also in type 1 diabetes with nearly no hypoglycemia impact. GLP-1 analogues help diabetic and non-diabetic obese patients lose weight, according to a study published in the journal Obesity Review (2017). Liraglutide, a GLP-1 analogue, is already approved for the treatment of obesity and overweight patient, which is expected to fuel the growth of the GLP-1 analogs market.

The market for Glucagon-like peptide-1 analogues is predicted to develop because to the high prevalence of diabetes in the United States and Asia-Pacific.

GLP-1 analogues are administered via subcutaneous injection using an injectable pen, and are relatively expensive (US$ 492 for 30-day therapy) when compared to traditional type-2 diabetes medications such as insulin sensitizers and secretagogues (US$ 5-9 for 30-day therapy), which is a major factor limiting market growth. There's also the question of patient compliance. GLP-1 analogues, for example, must be provided via injection as opposed to other anti-diabetic drugs, which are taken orally in tablet form.

Comments

Post a Comment

Popular posts from this blog

One of the primary factors driving the Worldwide Frosting and Icing Market is the rising demand for cakes and pastries.

Image
  Market Dynamics The increased demand for cakes and pastries is one of the key reasons driving the global frosting and icing market . According to Agriculture and Agri-Food Canada, the value of cakes sold in the United Kingdom increased by an average of 2% every year from 2012 to 2017, outpacing the CAGR by 1.5 percent (2007-2012). Furthermore, an increase in the number of bakeries as a result of increased urbanisation and rising income, which leads to a burgeoning food sector, is fueling the expansion of the frosting and icing market. In 2015, India's food processing business was valued at US$ 258 billion, according to the India Brand Equity Foundation (IBEF), ranking fifth in terms of consumption, output, and exports. Health issues, such as increased obesity, are, however, restraining market growth. In 2017, 36.5 percent of adults in the United States were obese, according to the Centers for Disease Control and Prevention (CDC), which impeded market expansion. To tackle this, a ...
Read more

Orthopedic Power Tools Market predicted to be growing at a CAGR of 3.50 percent over the forecast period (2020-2027)

Image
Various orthopaedic illnesses in the musculoskeletal systems, such as musculoskeletal trauma, spine diseases, musculoskeletal injuries, and infections, are treated by orthopaedics. Orthopedic power tools are lightweight, user-friendly, and easy to handle when performing orthopaedic surgery when compared to traditional heavy orthopaedic tools. Electric powered orthopaedic tools, battery operated power systems, and pneumatic power tools are the three types of orthopaedic power tools. In 2020, the global orthopaedic power tools market is predicted to be worth US$ 943.8 million, growing at a CAGR of 3.50 percent over the forecast period (2020-2027). One of the reasons predicted to drive market expansion during the forecast period is the rising frequency of spinal injuries. According to a report issued by the National Spinal Cord Injury Statistical Center in 2018, the incidence of spinal cord injury in the United States is roughly 54 instances per one million individuals, with around 17,70...
Read more

The Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market will continue to increase as the number of ambulatory individuals seeking treatment for skin and skin structure infections rises

Image
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are infections of the epidermis, dermis, and subcutaneous tissues that affect the skin and soft tissues. ABSSSI is defined by the US FDA as lesions having cellulitis/erysipelas, wound infections, and large cutaneous abscesses with a surface area of at least 75 cm2. ABSSSI is caused by pathogens such as Methicillin-sensitive Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, E. coli, Enterococcus faecalis, and Pseudomonas aeruginosa. The rising incidence of drug-resistant strains, particularly in Staphylococcus spp. and Enterococcus spp., makes this infection challenging to treat. The ABSSSI market is predicted to grow at a steady pace, thanks to an increasing number of patients suffering from these conditions and a significant number of pipeline treatments expected to be authorised during the forecast period. Acute Bacterial Skin and Skin Structure Infections (ABSSSI...
Read more